2Masmoudi K,Gras CV,Masson H,et al.Parkinsonism and,or cognitive impairment with valproic acid therapy:a report of ten cases[J].Pharmacopsychiatry,2006,39(1):9-12.
3Goetz CG,Poewe W,Rascol O,et al.Movement disorder society task force report on the Hoehn and Yahr staging scale:status and recommendations.Mov Disord,2004,19(9):1020-1028.
4Noebauer-Huhmann IM,Pinker K,Barth M,et al.Contrast-enhanced,high-resolution,susceptibility-weighted imaging of the brain:dose-dependent optimization at3tesla and1. 5tesla in healthy volunteers.Invest Radiol,2006,41(3):249-255.
5Sehgal V,Delproposto Z,Haacke EM,et al.Clinical applications of neuroimaging with susceptibility-weighted imaging.J Magn Reson Imaging,2005,22(4):439-450.
6Manova ES,Habib CA,Boikov AS,et al.Characterizing the mesencephalon using susceptibility-weighted imaging.Am J Neuroradiol,2009,30(3):569-574.
7Sitburana O,Ondo WG.Brain magnetic resonance imaging(MRI)in parkinsonian disorders.Parkinsonism Relat Disord,2009,15(3):165-174.
8Sehgal V,Delproposto Z,Haddar D,et al.Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses.J Magn Reson Imaging,2006,24(1):41-51.
9Benarroch EE.Brain iron homeostasis and neurodege-nerative disease.Neurology,2009,72(16):1436-1440.
10Zhang J,Zhang Y,Wang J,et al.Characterizing iron deposition in Parkinson's disease using suceptibility-weighted imaging:an in vivo MR study.Brain Res,2010,1330:124-130.
